Pfizer Inc. PFE
28.67
0.26
0.92%
as of 25 Sep
- Market cap
- $161.7B
- P/E
- 37.7×
Follow PFE
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Pfizer Inc. (PFE) Free cash flow margin
Pfizer Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 17.3%, up 2.8 percentage points from fiscal 2025 (14.5%). Over the past ten years it has ranged from 8.05% (fiscal 2023) to 36.7% (fiscal 2021); the current reading is higher than 18% of that period. That is in line with the Drug Manufacturers General industry median of 17.3% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 14.5% | (0.96) |
| FY2024 | 15.5% | 7.41 |
| FY2023 | 8.05% | (17.68) |
| FY2022 | 25.7% | (11.01) |
| FY2021 | 36.7% | 8.80 |
| FY2020 | 27.9% | 3.19 |
| FY2019 | 24.8% | (8.79) |
| FY2018 | 33.5% | 5.78 |
| FY2017 | 27.8% | 0.89 |
| FY2016 | 26.9% | (0.13) |
Against its own ten years
Low 8.05%
High 36.7%
Ten-year median
26.9%
Current reading's percentile
18
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| GILD Gilead Sciences, Inc. compare | 42.5% |
| NVS Novartis AG compare | 26.8% |
| AMGN Amgen Inc. compare | 26.7% |
| SNY Sanofi compare | 25.5% |
| BMY Bristol Myers Squibb Company compare | 23.3% |
| PFE Pfizer Inc. | 17.3% |
| GSK GSK PLC Sponsored ADR compare | 17.2% |
| NVO Novo Nordisk A/S compare | 14.8% |
| AZN AstraZeneca PLC compare | 10.2% |
| Drug Manufacturers General industry median | 17.3% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on PFE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement